SYK Stryker Corporation

Look at the breakdown of Intuitive Surgical's revenue streams—Instruments and Accessories alone generate roughly 60% of the top line on a per-procedure basis. That tight link between surgery volume and cash flow explains why investors reacted so sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed. With recurring earnings visibility clouded, how much downside risk is the market actually pricing in.

Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.

Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is the giant, selling hospitals everything from hip and knee products to capital equipment. ResMed is a sleep device maker with less than a quarter of Stryker's revenue. Stryker costs 32.6 times its past year's earnings, against 21.9 times for ResMed. So does Stryker's reach justify that higher price? T

Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. procedure growth. The more telling number is 144 trade-ins in fiscal Q2 2026, up from 83 a year earlier. Most came from customers moving to the new da Vinci 5 robot. Those trade-ins matter most if upgrades continue and each surgery also earns more. Is that number a blip, or are customers still trading up.

General Dynamics (NYSE:GD) received a new multi year U.S. Army contract modification for Double V Hull A1 Stryker vehicles, extending through 2028. The award enlarges the Army Stryker program backlog and adds funded production for upgraded armored vehicles across multiple brigade combat teams. The contract update supports continued manufacturing at General Dynamics Land Systems facilities that produce Stryker chassis and mission packages. The extra Double V Hull A1 Stryker work is...

ISRG's rapid procedure growth, expanding robotics ecosystem and recurring revenues highlight its growth path amid MedTech shifts.

GD's Stryker contract modification lifts cumulative value to $278.9M, supporting Land Systems demand through December 2028.

SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.

Why Stryker’s new Foot & Ankle push matters for shareholders Stryker (SYK) is putting fresh attention on its Foot & Ankle franchise, rolling out new planning tools and limb reconstruction hardware at the 2026 AOFAS meeting in Seattle. The spotlight is on Prophecy Surgical Planning, now linked to the Incompass Total Ankle System, and on the Hoffmann LRF smartHEX platform, which extends the company’s reach into complex deformity correction supported by mobile software. Set against this product...

Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.

Stryker (NYSE:SYK) announced new Foot & Ankle portfolio updates, including expanded Prophecy Surgical Planning, at a major industry meeting. The company introduced the Hoffmann LRF smartHEX system, aimed at limb reconstruction and patient connectivity in complex cases. Expanded planning tools and patient specific technologies are intended to support surgeon decision making in ankle replacement procedures. The Prophecy Surgical Planning expansion and Hoffmann LRF smartHEX launch sit alongside...

Markets are wrestling with a Fed that sounds more willing to tolerate economic pain than investors expected, while supply shocks from oil and tariffs keep pressure on costs. That mix tends to push attention toward reliable cash flows and dividends, as many traders reassess how much risk they really want to hold. This article walks through three large-cap, income-focused stocks exposed to this macro backdrop and explains how each may factor into your portfolio decisions now. The stocks below...

Intuitive Surgical is expanding robotic surgery in ASCs with lower-cost XiR systems, opening access to new customers and outpatient procedures.

Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. That looks like a surgical-robot leader on sale, but the price history disagrees. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Intuitive Surgical (ISRG) has lost about 12% over the past year, while the S&P 500 returned about 17%. Most of the debate has been about the U.S. procedure growth slowing. The number that should worry a holder more is the money the company collects on the instruments used in each operation. Intuitive plans to lower it.

Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high. Even so, you pay about 35.9 times trailing adjusted earnings. That is normalized net income with stock-based compensation added back, a basis meant to sit closer to the one analysts forecast on, though the two are not defined identically. Analysts' forecasts run to 2027, the year Intuitive plans to start lowering what customers pay per use on some instruments.

Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.

Stryker (SYK) will likely see an acceleration story in 2027, with high single digit growth achievabl

SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.

GEHC vs. SYK: Which Stock Is the Better Value Option?

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 31.6% over the past six months, topping the S&P 500 by 17.9 percentage points.

Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their 8.6 high.

Stryker has seen its share price slide sharply over the past year, and the question now is whether the current valuation still lines up with the cash the business is expected to generate. For investors watching the stock after recent headlines, the focus has shifted from past returns to whether today's price fairly reflects those underlying cash flows. The stock has fallen 24.5% over the past year, which puts the spotlight on whether that move has brought the valuation closer to what its...

A medical device giant now costs more than its faster-growing rivals, forcing investors to decide if its premium price tag is buying durable quality or just yesterday's story.

BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.

Intuitive Surgical (ISRG) trades near $370, about 38% below its 52-week high, after growth in its US robotic-surgery procedures slowed. Selling a put pays you now for agreeing to buy the shares much lower, and you keep the payment either way. The catch is it only works if you would want this business at that price.

Boston Scientific (BSX) trades at about $43, roughly 17% below the recent high it set on 19th Aug, 2026. Its own history with sharp drops is encouraging. That history does not cover a cyberattack it says is likely to hit its 2026 results, and the stock is down about 60% over the past twelve months. Start with the history.

CFO Preston Wells said at a healthcare conference that the company is still working through supply issues in its peripheral vascular business and had fewer hip sales than expected so far this quarter.

Intuitive Surgical (ISRG) has handed its owners a hard year. The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a fall like that the natural hope is that the big moves are behind you. Options priced a year out say they are not.

Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.

Intuitive Surgical trades at its cheapest valuation in 10 years as strong growth, innovation and procedure gains face rising costs and market pressures.

Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "mater

Investing.com -- Stryker Corp. shares dropped as much as 7.7% on Tuesday morning after company executives discussed ongoing problems in its peripheral vascular and joint replacement operations at an industry conference.

Stryker Corporation (NYSE:SYK) signed a definitive agreement to acquire privately held ZuriMED, which would add the commercialized FiberLocker System to its shoulder portfolio upon closing. FiberLocker is designed to reinforce rotator-cuff repairs by strengthening the connection between a surgical patch and tendon tissue. The transaction remains subject to customary closing conditions, while the purchase price […]

While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.

Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.

BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.

SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Stryker (NYSE:SYK) and the best and worst performers in the medical devices & supplies - diversified industry.

In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.

The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.

The orthopedics specialist aims to launch a knee robot in late 2028, followed by a shoulder robot in 2029.

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index adding 0.7% and the

Stryker (NYSE:SYK) received FDA De Novo authorization for its SportSuite Vision software on Apple Vision Pro in a clinical setting. The company reported completion of the first surgical procedure using SportSuite Vision in an operating room environment. The software introduces augmented reality and spatial computing tools into surgical workflows and operating room visualization. The authorization marks a regulatory milestone for Stryker in mixed reality applications for healthcare. This...

Rotator cuff augmentation is one of the fastest-growing areas in sports medicine, according to Stryker.

SYK's planned ZuriMED acquisition adds the FiberLocker System, aiming to strengthen its shoulder portfolio and rotator cuff care capabilities.

Stryker has considerably underperformed the broader market over the past year, while analysts remain bullish on its future prospects.

This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.

Stryker stock has delivered a modest total return over the past five years, while the current intrinsic value estimate from a Discounted Cash Flow (DCF) framework suggests the shares trade at a discount to that internal calculation. At the same time, market based valuation multiples point to pricing that is broadly in line with peers, which leaves investors weighing two different valuation signals. Stryker has returned about 23.3% over the past five years, which points to a measured long...